Tranylcypromine/trifluoperazine
Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3]
| Combination of | |
|---|---|
| Tranylcypromine | Monoamine oxidase inhibitor |
| Trifluoperazine | Typical antipsychotic |
| Clinical data | |
| Trade names | Parstelin, Parmodalin, Jatrosom N, Stelapar |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
References
- Richard C. Dart (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
- Stephen M. Stahl (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
- Straker M, Grauer H (1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Can Med Assoc J. 85 (3): 127–30. PMC 1848140. PMID 20326829.
- Lothar Bruno Kalinowsky; Hanns Hippius; Helmfried E. Klein (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
| Typical |
|
|---|---|
| Disputed | |
| Atypical |
|
| Others |
|
| |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.